Related Experiment Video
Updated: Aug 7, 2026
Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions
Published on: November 30, 2022
Practical approaches to minimizing gastrointestinal and cardiovascular safety concerns with COX-2 inhibitors and
James M Scheiman1, A Mark Fendrick
1Division of Gastroenterology at the University of Michigan Medical Center, Ann Arbor, Michigan, USA. jscheima@med.umich.edu
Abstract:
Nonsteroidal anti-inflammatory drugs (NSAIDs) are highly effective in treating the pain and inflammation associated with osteoarthritis and rheumatoid arthritis, but it is well recognized that these agents are associated with substantial gastrointestinal toxicity. Treatment guidelines suggest that patients with one or more risk factors for NSAID associated ulcers should be prescribed preventive treatment. However, well over 80% of such patients may not receive an appropriate therapeutic intervention. Multiple strategies are available to reduce the risk for NSAID associated gastrointestinal complications. First, risk may be reduced by using non-NSAID analgesics. Second, use of the minimum effective dose of the NSAID may reduce risk. Third, co-therapy with a proton pump inhibitor or misoprostol may be desirable in at-risk patients. Use of cyclo-oxygenase-2 inhibitors may also reduce the risk for gastrointestinal events, although this benefit is eliminated in patients who receive aspirin, and cyclo-oxygenase-2 inhibitors may increase cardiovascular adverse events. The optimal management of NSAID related gastrointestinal complications must be based on the individual patient's risk factors for gastrointestinal and cardiovascular disease, as well as on the efficacy and tolerability of both the NSAID and accompanying gastroprotective agent.
Insights
Nonsteroidal anti-inflammatory drugs (NSAIDs) effectively manage arthritis pain but cause gastrointestinal issues. Preventive strategies, including alternative analgesics or gastroprotective agents, are crucial for at-risk patients but often underutilized.
Area of Science:
- Pharmacology
- Gastroenterology
- Rheumatology
Background:
- Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for osteoarthritis and rheumatoid arthritis pain and inflammation.
- NSAIDs are associated with significant gastrointestinal toxicity, including ulcer formation.
- Current guidelines recommend preventive treatment for NSAID-associated ulcers in high-risk patients.
Purpose of the Study:
- To review strategies for reducing NSAID-associated gastrointestinal complications.
- To highlight the underutilization of preventive therapies in at-risk patients.
- To emphasize individualized management based on patient risk factors.
Main Methods:
- Review of existing literature on NSAID gastrointestinal toxicity and prevention.
- Analysis of available risk-reduction strategies.
- Discussion of treatment guidelines and clinical practice.
Main Results:
- Over 80% of patients at risk for NSAID-associated ulcers do not receive appropriate preventive interventions.
- Risk reduction strategies include using non-NSAID analgesics, minimum effective NSAID doses, proton pump inhibitors, misoprostol, or cyclo-oxygenase-2 inhibitors.
- Cyclo-oxygenase-2 inhibitors may increase cardiovascular risks and lose gastroprotective benefits when co-administered with aspirin.
Conclusions:
- Optimal management requires assessing individual patient risks for gastrointestinal and cardiovascular events.
- Balancing NSAID efficacy and tolerability with gastroprotective agent safety is essential.
- Personalized treatment plans are necessary for managing NSAID-related gastrointestinal complications.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...